Navigation Links
Lilly Oncology to Unveil More Than 50 Studies at ASCO 2008
Date:5/1/2008

ALIMTA Lung Cancer Study Highlighting Key Histology Findings to Be Included

in May 15 ASCO Live, Online Presscast

INDIANAPOLIS, May 1 /PRNewswire-FirstCall/ -- Eli Lilly and Company will unveil data from more than 50 studies at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. from May 30 to June 3, 2008. The company will present the latest research findings on ALIMTA(R) (pemetrexed for injection), GEMZAR(R) (gemcitabine HCl for injection), and enzastaurin, an investigational, oral, targeted therapy. The majority of the studies being presented are findings that support Lilly's leadership in thoracic cancer research.

Of note is a pivotal Phase III study (ASCO Abstract # 8011) that demonstrated a key correlation between lung cancer histology (tissue type), treatment choice and patient outcome. It will be one of the studies featured on Thursday, May 15 in ASCO's live online presscast. The virtual press event will be the first time ASCO has selected researchers to present key abstracts prior to its annual meeting.

"Improved patient outcomes via tailored therapy continues to be our focus and this year's ASCO is no exception," said Richard Gaynor, M.D., Lilly vice president, cancer research and global oncology platform leader. "With Lilly studies focusing on thoracic and breast cancer, among others, this meeting will continue to show our commitment to answering the unmet needs of cancer care."

Key Pemetrexed Abstracts for ASCO 2008:

-- Abstract # 8011: June 2, 2008; 3:00 p.m.

-- Maintenance pemetrexed plus best supportive care (BSC) versus

placebo plus BSC: A phase III study

-- This study will be featured during ASCO presscast on May 15

-- Abstract # 8096: June 1, 2008; 2:00 p.m.

-- Comparison of patient outcomes stratified by histology among

pemetrexed-treated patients with stage IIIB/IV NSCLC in two Phase

II trials

-- Abstract # 8097: June 1, 2008; 2:00 p.m.

-- Resource utilization by non-small cell lung cancer histology:

Results from the randomized, phase III trial of

pemetrexed/cisplatin versus gemcitabine/cisplatin

For more information on Lilly Oncology agents, including full prescribing information, please visit http://www.lillyoncology.com .

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Lilly Declares Second-Quarter Dividend
2. Lilly to Streamline Indianapolis Manufacturing and Engineering Operations
3. Lilly Adjusts Time of Conference Call for First Quarter 2008 Financial Results Announcement
4. Lilly Sets Date and Conference Call for First Quarter 2008 Financial Results Announcement
5. State of Alaska and Eli Lilly and Company Reach Agreement to Settle Zyprexa Lawsuit
6. Statement from Eli Lilly and Company: Response to Todays New York Times Article, Lilly E-Mail Discussed Off-Label Drug Use
7. Lilly Grants $4.4 Million to the WHO for MDR-TB Program Expansion
8. Newly Labeled Therapies for Neuropathic Pain, Including Drugs From Pfizer and Eli Lilly, Will Drive Growth in the Chronic Pain Drug Market
9. Mental Health Parity Laudable, But House Legislation Would Put Medicaid Patients at Risk, Lilly Says
10. FDA Issues Not-Approvable Letter for Lillys Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
11. Lilly and Partners In Health, Brigham and Womens Hospital Team Up to Fight MDR-TB in Former Soviet Republics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... ... AlignLife clinics nationwide are giving back to their communities by collecting toys ... gifts wrapped tightly under a Christmas Tree. AlignLife hopes to spread the joy ... In exchange for generous donations, customers will receive a gift in return. Anyone ...
(Date:12/7/2016)... Honolulu, HI (PRWEB) , ... December 07, 2016 ... ... Dermatology is proud to announce that its fully redesigned website, which launched October ... well as a sleek responsive design and easy-to-navigate layout. Visitors and patients can ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... Top 20 Marketing Campaign Winner in the Folio: Marketing Awards competition. Live From ... the year’s best in pioneering, inventive, and ultimately successful projects undertaken by the ...
(Date:12/7/2016)... AZ (PRWEB) , ... December ... ... ElectroMedical Technologies, announced its newest portable bioelectronic medicine device WellnessPro Plus for ... WellnessPro Plus substantially enhances the WellnessPro platform by expanding the treatment modalities ...
(Date:12/7/2016)... ... 2016 , ... “Walking With God: Inspirational Lessons from My Life's Journey”: ... be aware of God's direction in their lives. “Walking With God: Inspirational Lessons from ... active church leader. , Sanford says, “I enjoy sharing the true stories ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... N.Y. , Dec. 6, 2016  Licenders is bringing their ... This new location in Park Slope at 203 13 th ... Brooklyn clientele. "Our goal is to ... treatment plans are designed to get children right back to class ... are 100% all natural and safe for the whole family," Licenders ...
(Date:12/6/2016)... 2016  "Blood Tests replace Surgical Biopsies. Single ... The Diagnostic, Monitoring and Screening Test opportunities are ... occurring using in vitro blood testing to identify ... backing, has announced a single blood test to ... than the market. New technology that definitively identifies ...
(Date:12/6/2016)... 6, 2016 Diabetes & Obesity Drug Development ... obesity disease cluster is currently dominated by therapeutics indicated ... diabetes mellitus (T2DM), and the majority of the pipeline, ... is attributable to these indications. While products indicated for ... there are a large number of these products in ...
Breaking Medicine Technology: